Search bioRxiv⌕ Search

Biology subjects

Gotoh, N.

Publications and source records attributed to Gotoh, N..

5 recordsLinked to original sources

Conformational dynamics of an intrinsically disordered receptor enable signal transduction

Signal transduction is initiated when activated cell-surface receptors physically engage intracellular signaling proteins. Although structural and biochemical studies have established the molecular architecture of receptor tyrosine kinase (RTK) signaling, the earliest dynamic events that couple receptor activation to intracellular signal propagation have remained inaccessible because existing approaches provide static structural snapshots or ensemble-averaged measurements rather than direct observation of molecular motion. Here, using high-speed atomic force microscopy (HS-AFM), we directly visualize these initial molecular events at the single-molecule level in real time. Using fibroblast growth factor receptor 1 (FGFR1) as a model, we show that receptor autophosphorylation releases its intrinsically disordered juxtamembrane region, enabling extensive conformational dynamics of the kinase domain that permit productive engagement of the signaling adaptor FRS2, a key initiator of downstream RTK signaling. In contrast, a kinase-inactive mutation or the clinically approved FGFR inhibitor futibatinib restricts receptor motion, stabilizes a compact receptor configuration, and markedly reduces adaptor engagement. Molecular dynamics simulations suggest that the disruption of inhibitory interactions between the juxtamembrane region and the kinase domain provides a structural explanation for the observed receptor dynamics. Together, our findings uncover a previously inaccessible physical mechanism underlying the initiation of RTK signaling and establish HS-AFM as a powerful platform for visualizing receptor dynamics, providing a framework for mechanistic studies of signal transduction and for the development and mechanistic evaluation of compounds that modulate receptor signaling.

biophysics↗

Highly plastic macrophage niches orchestrate acquired quiescence and reactivation in breast-cancer bone metastasis

Recurrence and metastasis remain major causes of cancer mortality, sustained by therapy-resistant micrometastatic cells. Bone is a frequent site of breast-cancer relapse, yet the cues that reawaken disseminated cells remain poorly defined. We identify a previously unrecognized, highly plastic CXCL16 macrophage population that integrates tumor-associated macrophage programs found in distant metastatic sites such as lung and brain with non-tumor disease-associated traits in bone marrow. These CXCL16 macrophages establish a transient niche that restrains disseminated cancer-cell proliferation. Single-cell transcriptomics delineate functional remodeling of myeloid niches within the bone metastatic microenvironment: a CXCL16 macrophage niche that transiently constrains metastatic growth, and G-CSF macrophage and neutrophil niches that reignite tumor outgrowth. In primary tumors, cancer-associated fibroblasts (CAFs) aberrantly secrete G-CSF in response to cancer-cell signals, expanding G-CSF-receptor-positive subset of cancer cells with high metastatic potential. In advanced human bone metastases, CXCL16 macrophages localize to CAF-rich stroma but are excluded from cancer-cell clusters, indicating immune evasion. Together, these findings uncover CAF-bone-marrow cross-talk as a therapeutic target linking stromal inflammation, immune remodeling, and metastatic progression.

cancer biology↗

Mitochondrial one-carbon enzyme MTHFD1L sustains stemness and metastatic progression in breast cancer

One-carbon (1C) metabolism is frequently upregulated in cancer to support anabolic growth and nucleotide biosynthesis. However, the contribution of mitochondrial 1C metabolism to cancer stemness and metastatic progression remains incompletely understood. Here, we identify methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L), a mitochondrial 1C metabolic enzyme, as a critical regulator of breast cancer stemness, tumor initiation, and lung metastasis. Genetic depletion of MTHFD1L in triple-negative breast cancer (TNBC) cell lines and patient-derived breast cancer models markedly impaired proliferation, sphere formation, tumorigenicity, and lung colonization. Metabolomic profiling revealed extensive metabolic rewiring following MTHFD1L loss, characterized by accumulation of the purine biosynthetic intermediates SAICAR and AICAR together with perturbations in glycolytic and pentose phosphate pathways. Importantly, suppression of lung metastasis was accompanied by reduced expression of the stemness-associated transcription factor SOX2 and decreased proliferative activity in metastatic lesions. Collectively, our findings establish MTHFD1L as a key metabolic dependency linking mitochondrial 1C metabolism to stem-like properties and metastatic progression in breast cancer, and highlight MTHFD1L as a promising therapeutic target in metastatic TNBC.

Cancer Biology↗

HSD11β1 promotes EMT-mediated breast cancer metastasis

Abnormal biosyntheses of steroid hormones and dysregulation of steroid hormone receptors contribute to breast cancer metastasis but the mechanisms of that are poorly understand. Here we report a stress hormone producing enzyme, Hydroxysteroid (11-Beta) Dehydrogenase 1 (HSD11{beta}1) promotes breast cancer metastasis. HSD11{beta}1 was ectopically expressed in seventy-one percent of triple-negative breast tumors and correlated with shorter overall survival. HSD11{beta}1 significantly promoted breast cancer metastasis through induction of epithelial-to-mesenchymal transition (EMT); conversely, pharmacologic and genetic inhibition of HSD11{beta}1 suppressed metastatic progression of breast cancer cells. Moreover, 11-hydroxyprogesterone (11-OHP) whom HSD11{beta}1 produced in breast cancer cells, conferred metastatic properties on non-metastatic breast cancer cells through induction of EMT. We identified Peroxisome Proliferator-activated Receptor Alpha (PPAR-) as essential for both HSD11{beta}1 and 11OHP-driven EMT. Knockdown of PPAR- induced MET on HSD11{beta}1-expressing breast cancer cells. Taken together, HSD11{beta}1 promotes breast cancer metastasis and would be a novel target for suppressing breast cancer metastasis.

cancer biology↗

MCM10 compensates for Myc-induced DNA replication stress in breast cancer stem-like cells

Cancer stem-like cells (CSCs) are responsible for the drug resistance of tumors and recurrence while they experience DNA replication stress. However, the underlying mechanisms that cause DNA replication stress in CSCs and how they compensate for this stress remain unclear. Here we provide evidence that upregulated c-Myc expression induces stronger DNA replication stress in patient-derived breast CSCs than in differentiated cancer cells. Our results suggest critical roles for mini-chromosome maintenance protein 10 (MCM10), which is a firing (activating) factor of the DNA replication origins, to compensate for the DNA replication stress. Expression levels of MCM10 are upregulated in CSCs and maintained by c-Myc. c-Myc-dependent collisions may take place between RNA transcription and DNA replication machinery in nuclei, thereby causing DNA replication stress. MCM10 may activate dormant replication origins close to the collisions to ensure replication progression. Moreover, patient-derived breast CSCs were dependent on MCM10 for their maintenance even after enrichment for CSCs that were resistant to paclitaxel, the standard chemotherapeutic agent. In addition, MCM10 depletion decreased the growth of cancer cells but not normal cells. Therefore, MCM10 is likely to robustly compensate for DNA replication stress and facilitate genome duplication in the S-phase in cancer cells, which is more pronounced in CSCs. We provide a preclinical rationale to target the c-Myc-MCM10 axis to prevent drug resistance and recurrence.

cancer biology↗